Upcoming Participation in Global Healthcare Conference
BOSTON, Nov. 27, 2024 — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a biotechnology company in the clinical stage, is proud to announce its attendance at the upcoming Global Healthcare Conference organized by Citi. This significant event is scheduled to take place from December 3-5 in Miami, fostering dialogue and collaboration in the biotechnology and healthcare sectors.
About Sensei Biotherapeutics
Sensei Biotherapeutics specializes in the innovative field of biotechnology, particularly focused on discovering and developing next-generation therapeutics aimed at patients battling cancer. Utilizing its unique TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei is creating conditionally active therapeutics that strategically target the tumor microenvironment. This approach is designed to either inhibit immunosuppressive signals or stimulate immunostimulatory signals within the tumor, hence unleashing T cells to effectively attack cancer cells.
Focus on Advanced Therapeutics
The company’s lead candidate, SNS-101, is a pioneering therapeutic that targets the V-domain Ig suppressor of T cell activation (VISTA) checkpoint. This groundbreaking antibody is specifically crafted to act within the acidic environment of tumors, where VISTA functions to suppress immune responses by binding to the PSGL-1 receptor. By blocking this interaction, SNS-101 aims to enhance the immune system's ability to combat tumors.
Company's Vision and Goals
Sensei Biotherapeutics is committed to transforming cancer treatment through innovative solutions that empower the body’s immune response. With a focus on rigorous scientific research and robust clinical trials, the company is strategically advancing its pipeline to bring safe and effective therapies to market. Their dedication to exploring and understanding cancer’s mechanisms provides a strong foundation for their therapeutic developments, positioning them as a leader in the biotherapeutic landscape.
Networking and Future Interactions
Participating in Citi’s 2024 Global Healthcare Conference represents an invaluable opportunity for Sensei Biotherapeutics to network with industry experts, investors, and other stakeholders who are passionate about advancing healthcare solutions. The company is eager to share its advancements with a broader audience and establish potential collaborations that can accelerate the development and commercialization of its promising therapeutics.
Investor Engagement Strategy
For inquiries and discussions regarding investment opportunities, the company's Investor Relations team is available to provide insights into Sensei’s strategic direction and pipeline development. Interested parties are encouraged to reach out directly for discussions that can lead to mutually beneficial collaboration.
Additional Information and Contact
Stakeholders can find more information about Sensei Biotherapeutics and its innovative approaches by exploring their official website, where regular updates and insights are provided. Furthermore, the management encourages following the company on social media platforms to stay informed about corporate news and future initiatives.
Frequently Asked Questions
What is Sensei Biotherapeutics?
Sensei Biotherapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment.
What is TMAb™ technology?
TMAb™ stands for Tumor Microenvironment Activated biologics, which is a platform used by Sensei to create therapeutics targeting the tumor environment.
What is SNS-101?
SNS-101 is an innovative therapeutic product candidate designed to block the VISTA checkpoint specifically in cancerous tissues.
When is the Citi Global Healthcare Conference?
The conference will take place from December 3 to 5, providing a venue for discussions on healthcare innovations.
How can I contact Sensei Biotherapeutics?
For inquiries, you can reach out to Michael Biega, Senior Director of Investor Relations, through the provided investor email contact.
